CasBio Announces Strategic Collaboration with DxD Hub to Advance CRISPR-Based STI Diagnostics
CasBio is pleased to announce a strategic collaboration with the Diagnostics Development Hub (DxD Hub), a national platform hosted by the Agency for Science, Technology and Research (A*STAR), Singapore to accelerate the development and translation of advanced CRISPR-based diagnostic platforms for sexually transmitted infections (STIs), including gonorrhea and chlamydia.
CRISPR is a gene-editing tool that can also be adapted to detect specific genetic material, enabling fast and highly precise diagnostic testing. Under this partnership, CasBio’s proprietary CRISPR technology will be supported by DxD Hub’s clinical development expertise, and regulatory guidance. The collaboration aims to streamline assay development, enhance analytical performance, and enable rapid, accurate, and user-friendly testing at the point of care.
The collaboration focuses on developing rapid point-of-care tests that deliver laboratory-quality accuracy without the need for complex equipment or specialized laboratory environments. These innovations are designed to support early detection, timely treatment, and reduced transmission – particularly in community, health-conscious, and resource-limited settings.
“Our partnership with DxD Hub is an important milestone in translating our technology from the laboratory into real-world healthcare settings,” said Prof Ghasem Hosseini Salekdeh from CasBio. “By pairing transformative biotechnology with strong clinical translational capabilities, we are positioned to deliver rapid and accurate STI diagnostics that can significantly improve patient outcomes and public health.”
“We are excited to partner with CasBio in bringing novel CRISPR diagnostics into clinical use,” said Dr Weng Ruifen, Chief Executive Officer of DxD Hub. “This collaboration will help translate CRISPR innovation into reliable and user-friendly point-of-care tests for more timely diagnostics and effective management of diseases such as STIs.”
About CasBio
CasBio is a biotechnology startup developing advanced diagnostic and therapeutic solutions powered by CRISPR and nanotechnology. Casbio is committed to translating groundbreaking molecular innovations into practical tools for human and animal health, with a focus on real-world clinical impact. To learn more, visit https://casbio.bio
About DxD Hub
The Diagnostics Development Hub (DxD Hub) is a national platform hosted by Singapore’s Agency for Science, Technology and Research (A*STAR). It enables efficient and effective productisation of fit-for-purpose In-Vitro Diagnostics and Digital Health solutions for health and economic impact. DxD Hub has cross-cutting, multidisciplinary diagnostics product development capabilities that spans across Molecular Diagnostics, Proteomics, Digital Health and Integrated Point-of-Care diagnostics. We work with public and private partners, supporting the transformation of the Medtech landscape in Singapore through innovative solutions. For ongoing news, visit https://www.a-star.edu.sg/dxdhub
About Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR’s R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.